STOCK TITAN

[144] GENPACT LIMITED SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Genpact Limited submitted a Form 144 notice for the proposed sale of 2,326 common shares, with an aggregate market value of $100,413.42. The shares represent a small fraction of the issuer's outstanding common stock (174,270,076 shares outstanding) and were acquired as restricted stock on 12/31/2019. The broker listed is Morgan Stanley Smith Barney LLC and the securities are designated for sale on the NYSE with an approximate sale date of 08/12/2025. The form indicates no securities sold in the past three months and includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.

Genpact Limited ha presentato un avviso Form 144 per la vendita proposta di 2,326 azioni ordinarie, con un valore di mercato complessivo di $100,413.42. Le azioni rappresentano una piccolissima parte delle azioni in circolazione dell'emittente (174,270,076 azioni in circolazione) e sono state acquisite come azioni soggette a restrizioni il 31/12/2019. Il broker indicato è Morgan Stanley Smith Barney LLC e i titoli sono destinati alla vendita sulla NYSE con data di vendita approssimativa del 12 agosto 2025. Il modulo indica che non sono stati venduti titoli negli ultimi tre mesi e include la dichiarazione del firmatario di non essere a conoscenza di informazioni materiali avverse non divulgate relative all'emittente.

Genpact Limited presentó un aviso Form 144 para la venta propuesta de 2,326 acciones ordinarias, con un valor de mercado agregado de $100,413.42. Las acciones representan una pequeña fracción del capital social en circulación del emisor (174,270,076 acciones en circulación) y fueron adquiridas como acciones restringidas el 31/12/2019. El intermediario consignado es Morgan Stanley Smith Barney LLC y los valores están destinados a la venta en la NYSE con fecha aproximada de venta el 12 de agosto de 2025. El formulario indica que no se han vendido valores en los últimos tres meses e incluye la declaración del firmante de que no tiene conocimiento de información material adversa no divulgada sobre el emisor.

Genpact Limited2,326주의 보통주 매도 예정에 대해 Form 144 통지를 제출했으며, 총 시가액은 $100,413.42입니다. 해당 주식은 발행주식 총수(174,270,076주)의 극히 일부에 해당하며 2019년 12월 31일 제한주로 취득되었습니다. 기재된 중개인은 Morgan Stanley Smith Barney LLC이며, 해당 증권은 NYSE에서 매각될 예정으로 2025년 8월 12일경 매각될 것으로 보입니다. 양식에는 최근 3개월간 매도된 증권이 없다고 기재되어 있으며, 서명인은 발행인에 관한 공개되지 않은 중요한 불리한 정보가 없음을 진술하고 있습니다.

Genpact Limited a déposé un avis Form 144 pour la cession proposée de 2,326 actions ordinaires, d'un valeur de marché totale de $100,413.42. Les actions représentent une petite fraction du capital social en circulation de l'émetteur (174,270,076 actions en circulation) et ont été acquises en tant que actions restreintes le 31/12/2019. Le courtier indiqué est Morgan Stanley Smith Barney LLC et les titres sont destinés à la vente sur la NYSE avec une date approximative de vente le 12 août 2025. Le formulaire indique aucun titre vendu au cours des trois derniers mois et inclut la déclaration du signataire selon laquelle il n'a connaissance d'aucune information défavorable importante non divulguée concernant l'émetteur.

Genpact Limited hat ein Form-144-Meldeformular für den geplanten Verkauf von 2,326 Stammaktien eingereicht, mit einem Gesamtmarktwert von $100,413.42. Die Aktien stellen einen kleinen Bruchteil des ausstehenden Stammkapitals des Emittenten dar (174,270,076 ausstehende Aktien) und wurden am 31.12.2019 als gesperrte Aktien erworben. Als Broker ist Morgan Stanley Smith Barney LLC aufgeführt, und die Wertpapiere sind zum Verkauf an der NYSE bestimmt, mit einem voraussichtlichen Verkaufsdatum am 12. August 2025. Das Formular gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enthält die Erklärung des Unterzeichners, dass ihm keine nicht offengelegten wesentlichen negativen Informationen über den Emittenten bekannt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, routine Form 144 notice; transaction size is immaterial to Genpact’s market capitalization.

The filing reports a proposed sale of 2,326 restricted shares valued at about $100k against 174.27 million shares outstanding, representing a de minimis percentage of equity and unlikely to move market prices or alter fundamentals. The use of a major broker and the absence of any sales in the prior three months suggest this is a controlled, compliance-driven disclosure rather than a signal of material change. Impact is neutral for investors.

TL;DR: Disclosure appears procedurally correct and non-material; signature attests to lack of undisclosed adverse information.

The notice documents acquisition as restricted stock and lists broker and exchange details, meeting Rule 144 disclosure norms. The filer’s representation regarding material information is standard and important for regulatory compliance. Given the small lot size and clear acquisition history, this filing raises no governance red flags or material control issues for shareholders.

Genpact Limited ha presentato un avviso Form 144 per la vendita proposta di 2,326 azioni ordinarie, con un valore di mercato complessivo di $100,413.42. Le azioni rappresentano una piccolissima parte delle azioni in circolazione dell'emittente (174,270,076 azioni in circolazione) e sono state acquisite come azioni soggette a restrizioni il 31/12/2019. Il broker indicato è Morgan Stanley Smith Barney LLC e i titoli sono destinati alla vendita sulla NYSE con data di vendita approssimativa del 12 agosto 2025. Il modulo indica che non sono stati venduti titoli negli ultimi tre mesi e include la dichiarazione del firmatario di non essere a conoscenza di informazioni materiali avverse non divulgate relative all'emittente.

Genpact Limited presentó un aviso Form 144 para la venta propuesta de 2,326 acciones ordinarias, con un valor de mercado agregado de $100,413.42. Las acciones representan una pequeña fracción del capital social en circulación del emisor (174,270,076 acciones en circulación) y fueron adquiridas como acciones restringidas el 31/12/2019. El intermediario consignado es Morgan Stanley Smith Barney LLC y los valores están destinados a la venta en la NYSE con fecha aproximada de venta el 12 de agosto de 2025. El formulario indica que no se han vendido valores en los últimos tres meses e incluye la declaración del firmante de que no tiene conocimiento de información material adversa no divulgada sobre el emisor.

Genpact Limited2,326주의 보통주 매도 예정에 대해 Form 144 통지를 제출했으며, 총 시가액은 $100,413.42입니다. 해당 주식은 발행주식 총수(174,270,076주)의 극히 일부에 해당하며 2019년 12월 31일 제한주로 취득되었습니다. 기재된 중개인은 Morgan Stanley Smith Barney LLC이며, 해당 증권은 NYSE에서 매각될 예정으로 2025년 8월 12일경 매각될 것으로 보입니다. 양식에는 최근 3개월간 매도된 증권이 없다고 기재되어 있으며, 서명인은 발행인에 관한 공개되지 않은 중요한 불리한 정보가 없음을 진술하고 있습니다.

Genpact Limited a déposé un avis Form 144 pour la cession proposée de 2,326 actions ordinaires, d'un valeur de marché totale de $100,413.42. Les actions représentent une petite fraction du capital social en circulation de l'émetteur (174,270,076 actions en circulation) et ont été acquises en tant que actions restreintes le 31/12/2019. Le courtier indiqué est Morgan Stanley Smith Barney LLC et les titres sont destinés à la vente sur la NYSE avec une date approximative de vente le 12 août 2025. Le formulaire indique aucun titre vendu au cours des trois derniers mois et inclut la déclaration du signataire selon laquelle il n'a connaissance d'aucune information défavorable importante non divulguée concernant l'émetteur.

Genpact Limited hat ein Form-144-Meldeformular für den geplanten Verkauf von 2,326 Stammaktien eingereicht, mit einem Gesamtmarktwert von $100,413.42. Die Aktien stellen einen kleinen Bruchteil des ausstehenden Stammkapitals des Emittenten dar (174,270,076 ausstehende Aktien) und wurden am 31.12.2019 als gesperrte Aktien erworben. Als Broker ist Morgan Stanley Smith Barney LLC aufgeführt, und die Wertpapiere sind zum Verkauf an der NYSE bestimmt, mit einem voraussichtlichen Verkaufsdatum am 12. August 2025. Das Formular gibt an, dass in den letzten drei Monaten keine Wertpapiere verkauft wurden, und enthält die Erklärung des Unterzeichners, dass ihm keine nicht offengelegten wesentlichen negativen Informationen über den Emittenten bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Genpact (G) Form 144 notice disclose?

It discloses a proposed sale of 2,326 common shares with an aggregate market value of $100,413.42, to be sold on the NYSE via Morgan Stanley Smith Barney LLC.

When were the shares acquired that are proposed for sale in Genpact (G)?

The shares were acquired on 12/31/2019 and are described as restricted stock.

Are any Genpact (G) securities reported sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Who is the broker and what is the approximate sale date in the Form 144 for Genpact (G)?

Broker: Morgan Stanley Smith Barney LLC. Approximate sale date: 08/12/2025.

How large is the proposed sale relative to Genpact’s outstanding shares?

The proposed 2,326 shares are a very small portion of the 174,270,076 shares outstanding reported in the form.
Genpact Limited

NYSE:G

G Rankings

G Latest News

G Latest SEC Filings

G Stock Data

7.71B
159.95M
0.91%
103.71%
3.97%
Information Technology Services
Services-management Consulting Services
Link
Bermuda
HAMILTON